Denmark Biotechnology & Medical Research

Genmab A/S (GMAB)

Track

Track

Genmab A/S has recorded no insider trading activity within the past ninety days. The most recent transaction occurred on February 19, 2026, when the Chief Financial Officer sold shares. Previous filings include divestments by board members and officers dating back to 2025, reflecting historical patterns of equity liquidation by company leadership.
Ticker: GMAB Exchange: CPH
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Genmab A/S. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.9
Anthony Pagano Executive Vice President & Chief Financial Officer Officer
Transaction date
Sale
Price
130.52
Quantity 85,982
Value DKK3,029,783
2.1
Martin Schultz Member of the Board of Directors Executive Director
Transaction date
Sale
Price
354.21
Quantity 2,513
Value DKK1,818,883
Klimovsky Judith V Director Non-Executive Director
Transaction date
Proposed sale
Price
378.04
Quantity 80,815
Value US$1,578,430
Klimovsky Judith V Officer Officer
Transaction date
Proposed sale
Price
275.00
Quantity 1,200
Value US$330,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-20 2026-02-19 S Sale
2.9
Anthony Pagano

Executive Vice President & Chief Financial Officer

Officer
85,982
130.52
DKK3,029,783 		85,982 130.52 DKK3,029,783
2025-11-19 2025-11-19 S Sale
2.1
Martin Schultz

Member of the Board of Directors

Executive Director
2,513
354.21
DKK1,818,883 		2,513 354.21 DKK1,818,883
2025-06-17 2025-06-17 PrS Proposed sale
Klimovsky Judith V

Director

Non-Executive Director
80,815
378.04
US$1,578,430 		80,815 378.04 US$1,578,430
2024-03-01 2024-03-01 PrS Proposed sale
Klimovsky Judith V

Officer

Officer
1,200
275.00
US$330,000 		1,200 275.00 US$330,000
Explore more

More insider trading research around Genmab A/S

More insider trades in Denmark
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Europe
Insider trades in Europe Stoxx 600